Landscapes / Targets
CD123
13 drugs act on CD123, in 14 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs13
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
AbbVie · Public ABBV |
Approved | Feb 2027Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm and 1 more | ||||
| Open drug page | |||||
CD123 Interaction; cytotoxin |
Approved | 9 Feb 2028Phase 2 trial completes | |||
| Next date | 9 Feb 2028 · Phase 2 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and 5 more | ||||
| Open drug page | |||||
— |
Phase 1 | Nov 2026soonPhase 1 trial completes | |||
| Next date | Nov 2026 · Phase 1 trial completes | ||||
| Also tested for | Leukemia, Acute Myeloid, Myelodysplastic Syndromes and 6 more | ||||
| Open drug page | |||||
— |
Phase 1 | May 2027Phase 1 trial completes | |||
| Next date | May 2027 · Phase 1 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | ||||
| Open drug page | |||||
— |
Phase 1 | May 2027Phase 1 trial completes | |||
| Next date | May 2027 · Phase 1 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | ||||
| Open drug page | |||||
CD123 targeted CAR-NK cellsnot checked |
— |
Phase 1 | 30 Jun 2027Phase 1 trial completes | ||
| Next date | 30 Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) | ||||
| Open drug page | |||||
— |
Phase 1 | Dec 2028Phase 1 trial completes | |||
| Next date | Dec 2028 · Phase 1 trial completes | ||||
| Open drug page | |||||
— |
Gilead (Kite) · Public GILD |
Phase 1 | — | ||
| Also tested for | Acute Myeloid Leukemia, Myelodysplastic Syndromes | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Relapsed / Refractory AML, Relapsed / Refractory MDS | ||||
| Open drug page | |||||
— |
Gilead (Kite) · Public GILD |
Phase 1 | — | ||
| Also tested for | Acute Myeloid Leukemia, Myelodysplastic Syndromes | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Relapsed/Refractory Acute Myeloid Leukemia | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 12 of 13 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026